Advanced Search

Secondoprocedura Renewal Of Marketing Authorisation For The Medicinal Product For Human Use Mutual Recognition, «Medikinet», Resulting In A Review Printed.

Original Language Title: Rinnovo dell'autorizzazione all'immissione in commercio, secondoprocedura di mutuo riconoscimento, del medicinale per uso umano«Medikinet», con conseguente modifica stampati.

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
Retrieved determines the 6/2015 January 13, 2015 MEDIKINET # PV product: packaging: 041438 019 "5 mg modified release capsules" 28 capsules in blister PVC/PVDC-AL 041438 021 "5 mg modified release capsules 30 capsules" in PVC/PVDC-to 10 mg modified release capsules 041438 033 "" 28 capsules in blister PVC/PVDC-AL 041438 045 "10 mg modified release capsules 30 capsules" in PVC/PVDC-AL 041438 058 "20 mg capsules in 28 "modified-release capsules in blister PVC/PVDC-AL 041438 060" 20 mg modified release capsules 30 capsules "in PVC/PVDC-AL 041438 072" 30 mg modified release capsules "28 capsules in blister PVC/PVDC-AL 041438 084" 30 mg modified release capsules 30 capsules "in PVC/PVDC-AL 041438 096" 40 mg modified release capsules "28 capsules in blister PVC/PVDC-AL 041438 108" 40 mg modified release capsules 30 capsules " PVC/PVDC-AL Mah: MEDICE ARZNEIMITTEL PÜTTER GMBH & co. KG mutual recognition Procedure DE/H/2223/001-005/R/001 with the November 11, 2013 deadline it renewed, with unlimited validity, the marketing authorisation subject to amendment of the summary of product characteristics, package leaflet and labelling and on condition that, on the date of entry into force of this determination, the quality requirements , safety and efficacy are still present.
Changes must be made immediately to the summary of the product characteristics as per the package leaflet and labelling no later than six months after its publication in the Official Gazette of the Italian Republic of this determination.
In accordance with art. 80, paragraphs 1 and 3, of Legislative Decree No 219 April 24, 2006 and s leaflet and labels must be written in Italian and, limited to medicinal products marketed in the province of Bolzano, in German. The mAh avails itself of the complementary use of foreign languages, must give prior notice to the AIFA and keep available the certified translation of German texts and/or in another foreign language. In case of non-compliance with the provisions on the labelling and package leaflet shall apply sanctions under art. 82 of the Decree.
Both lots already products as of the date of publication in the official journal of the Italian Republic of this determination that the batches produced during the period referred to in art. 2, paragraph 2, of the aforementioned determination, which did not indicate the changes authorized, can be kept on the market until the expiration date printed on the label of the medicine. Pharmacists are required to deliver the package leaflet updated users as from the end of 30 days from the date of publication in the Official Gazette of the Italian Republic of this determination. The mAh makes accessible to pharmacist leaflet updated within the same timeframe.
This determination takes effect from the day following that of its publication in the official journal of the Italian Republic and will be notified to the company holder of the marketing authorisation of the medicinal product.